G-105 HIV vaccines based on transition state envelope structures

    loading  Checking for direct PDF access through Ovid


Protective efficacy from an HIV vaccine will heavily depend on anti-envelope antibodies that block the entry and spread of diverse viral strains. Thus, an HIV vaccine will have to generate humoral responses that focus on highly conserved and functional epitopes and thereby mediate their antiviral effects. Accordingly, we have been developing HIV vaccine strategies based on observations that very highly conserved epitopes are presented on HIV gp120 as it transitions through different structural states during viral entry. Here we will describe progress in the clinical development of an immunogen (FLSC) designed to mimic transition state gp120 structures along with new imaging data that elucidates potential virological explanations for vaccine effects.

Related Topics

    loading  Loading Related Articles